Gefitinib 與Erlotinib 皆為第一代口服表皮生長因子受體- 酪胺酸磷酸激活酶之抑制劑 (EGFR-TKIs)，可做為晚期非小細胞肺癌之口服治療用藥。儘管多數的病人初期使用EGFR-TKIs 都有很好的療效，然而終究還是會面臨到抗藥性的發生而導致疾病惡化。由於目前對於EGFR-TKIs 產生抗藥性後沒有一個標準的治療方案，因此本文藉由一位有EGFR 基因突變的晚期肺腺癌男性個案來探討使用Gefitinib 治療產生抗藥性後之後續治療計畫、治療成效與相關文獻探討。
 

Gefitinib and Erlotinib both are the first-generation oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which have excellent antitumor effects against advanced or recurrent non-small cell lung cancer (NSCLC). Despite initially showing a good response, most patients present with recurrence of the disease; this is due to the development of resistance to EGFR-TKIs. Since the lack of a standard therapeutic option for NSCLC patients who have progressive disease after EGFRTKIs failure, this article discussed the subsequent treatment choices for patients with acquired resistance to gefitinib by an EGFR mutation with advanced adenocarcinoma male patient.